close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

123.74 +4.44 (+3.72%)
Streaming Delayed Price Updated: 3:51 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property
Merck & Co. Inc. (NYSE:MRK) Emerges as a Strong Dividend Contender Through Methodical Screening ↗
Via Chartmill
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead. 
Via Stocktwits
Topics Intellectual Property
News headline image
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades ↗
The company might bend, but it won't break. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement? ↗
Merck has an attractive yield and a long history of dividend growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗
The comments come as ImmunityBio pushes for broader global access to Anktiva across indications. 
Via Stocktwits
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
8 Cheap Stocks to Buy in 2026 ↗
All 8 stocks with big upside 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
These two stocks have historically zigged when the market has zagged. 
Via The Motley Fool
Topics Stocks
News headline image
Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗
And now may be the right time to look for something other than artificial intelligence (AI)-driven growth. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s... 
Via MarketMinute
Topics Earnings
News headline image
Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗
Eli Lilly announced an acquisition of an innovative new autoimmune drug. 
Via The Motley Fool
News headline image
Dow Jones 267-Point Slide: Blue-Chip Leaders and the AI Reality Check
The Dow Jones Industrial Average endured a chilling session this Friday, February 13, 2026, dropping 267.77 points, or 0.54%, to close at 49,184.21. The slide marked the second consecutive day of... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
3 Mega-Cap Stocks for Long-Term Investors
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Topics Supply Chain
News headline image
The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle
The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026
As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
5 Revealing Analyst Questions From Merck’s Q4 Earnings Call
Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management... 
Via StockStory
Topics Earnings Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today